Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × epratuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 6 Lymphoma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Burkitt Lymphoma 3 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Recurrence 1 Leukemia 1

Interventions

Cyclophosphamide 132 Dexamethasone 108 Rituximab 71 fludarabine 64 Cytarabine 58 Lenalidomide 57 Gemcitabine 54 fludarabine phosphate 48 Bortezomib 47 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 41 Cisplatin 40 pomalidomide 37 Peripheral Blood Stem Cell Transplantation 37 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Calcium Dobesilate 30 Busulfan 30 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 24 Nivolumab 24 Mycophenolic Acid 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡